Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of A166 versus T-DM1 in previously trastuzumab- and taxane-treated HER2-positive unresectable or metastatic breast cancer
CTR20231740Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab botidotin, trastuzumab emtansine in breast cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Jul 2023; status: active.
02
Drugs
trastuzumab botidotintrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231740.